



January 15, 2025

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

AnGes Initiates Sponsored Research Agreement with Stanford Medicine on the Development of Novel Genome-Edited Cancer Therapies

AnGes Inc. announces that it has entered into a sponsored research agreement with Stanford Medicine ("Stanford") regarding the development of novel cancer therapies using genome editing technology.

1. Outline

We have agreed to advance research and development of a novel genome-editing therapy for cancer by combining the nucleic acid drug delivery technology developed by Dr. Ramasamy Paulmurugan and Dr. Tarik Massoud at Stanford with the genome editing technology of EmendoBio Inc., a subsidiary of AnGes. The agreement is expected to lead to the development of new genome-editing therapies for cancer. First, we plan to develop a treatment for breast cancer using genome editing technology.

Details will be announced as soon as they are determined.

2. Outline of the counterparty

Name	Stanford School of Medicine
Location	California, United States

3. Period and Research Funds

Research Period	Approximately 2 years
research expenses	Approximately 1.3 million USD

4. Background of agreement to sponsored research

Stanford has been conducting advanced research in the development of new cancer therapies, including cancer cell-specific drug delivery systems, cancer radiation therapy, and cancer immunotherapy.

AnGes has been conducting research and development of intranasally administered DNA vaccines for two years and two months with Stanford. By further developing the DNA drug delivery technology obtained as a result of this research and combining it with EmendoBio's genome editing technology, we have agreed to pursue the research and development of a new cancer genome editing therapy that is expected to significantly increase the efficiency of

<p>(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.</p>



cancer radiation therapy and cancer immunotherapy. The agreement is expected to significantly increase the efficiency of cancer radiotherapy and cancer immunotherapy.

5. Future Outlook

Our current forecast for research and development expenses from this sponsored research is approximately 1.3 million USD over two years, and the Company's research and development expenses for the consolidated fiscal year ending December 31, 2025 will be reflected in its earnings forecast. We will promptly disclose any further events that should be disclosed in the future.

AnGes, Inc.
Public Relations & Investor Relations Group
<https://www.anges.co.jp/en/>

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.